Drug Profile
Atorvastatin/levamlodipine
Alternative Names: Levamlodipine/atorvastatinLatest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator CSPC Ouyi Pharmaceutical
- Class Amides; Antihyperlipidaemics; Antihypertensives; Dihydropyridines; Fatty acids; Fluorobenzenes; Heptanoic acids; Nicotinic acids; Pyrroles
- Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-III for Hyperlipidaemia in China (PO) (CSPC Ouyi Pharmaceutical, October 2021)
- 14 Oct 2021 Discontinued - Phase-III for Hypertension in China (PO) (CSPC Ouyi Pharmaceutical, October 2021)
- 06 Feb 2018 Chemical structure information added